The University of Texas MD Anderson Cancer Center activated an investigator- initiated Phase 1b clinical trial of Soricimed Biopharma’s lead drug candidate, SOR-C13, in late-stage pancreatic cancer.
The objectives of the Phase 1b trial are to refine dosing and further explore safety and efficacy of SOR-C13 in late-stage solid tumor cancer. An earlier Phase 1 trial concluded that SOR-C13 was safe and well tolerated, with preliminary indication of anticancer activity, including tumor regression in two late-stage pancreatic cancer patients.
The single arm, open label study of SOR-C13 will enroll approximately 36 patients with advanced solid tumor cancers, with an emphasis on enrolling patients with late-stage pancreatic cancer.
“We were intrigued by the positive efficacy signals we observed in the pancreatic cancer patients treated with SOR-C13 at our site in Soricimed’s Phase 1 clinical trial,” Dr. Siqing Fu, Prof. at the Department of Investigational Cancer Therapeutics at MD Anderson, said in a statement.
“With this next trial, among other critical data, we look to expand our data in pancreatic cancer patients and confirm the efficacy results seen earlier,” he added.
Dominique Dugourd, VP of R&D at closely-held Soricimed, said, “It is our hope that our commitment to research will eventually yield a novel therapy for patients with significant unmet treatment needs.”
